These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16706654)

  • 41. Age-related decrease in proteoglycan synthesis of human articular chondrocytes: the role of nonenzymatic glycation.
    DeGroot J; Verzijl N; Bank RA; Lafeber FP; Bijlsma JW; TeKoppele JM
    Arthritis Rheum; 1999 May; 42(5):1003-9. PubMed ID: 10323457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Maillard reaction inhibitors and their biological and therapeutic significance.
    Sztanke K; Pasternak K
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):156-8. PubMed ID: 15323184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo.
    Vasan S; Zhang X; Zhang X; Kapurniotu A; Bernhagen J; Teichberg S; Basgen J; Wagle D; Shih D; Terlecky I; Bucala R; Cerami A; Egan J; Ulrich P
    Nature; 1996 Jul; 382(6588):275-8. PubMed ID: 8717046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triosidines: novel Maillard reaction products and cross-links from the reaction of triose sugars with lysine and arginine residues.
    Tessier FJ; Monnier VM; Sayre LM; Kornfield JA
    Biochem J; 2003 Feb; 369(Pt 3):705-19. PubMed ID: 12379150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Microwave-assisted Maillard reactions for the preparation of advanced glycation end products (AGEs).
    Visentin S; Medana C; Barge A; Giancotti V; Cravotto G
    Org Biomol Chem; 2010 May; 8(10):2473-7. PubMed ID: 20448908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen.
    Urios P; Grigorova-Borsos AM; Sternberg M
    Diabetes Res Clin Pract; 2007 Aug; 77(2):337-40. PubMed ID: 17383766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apoptotic killing of fibroblasts by matrix-bound advanced glycation endproducts.
    Obrenovich ME; Monnier VM
    Sci Aging Knowledge Environ; 2005 Jan; 2005(4):pe3. PubMed ID: 15673817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intrinsic toxicity of glucose, due to non-enzymatic glycation, is controlled in-vivo by deglycation systems including: FN3K-mediated deglycation of fructosamines and transglycation of aldosamines.
    Szwergold BS
    Med Hypotheses; 2005; 65(2):337-48. PubMed ID: 15922110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Native protein glycoxidation and aging.
    Meli M; Frey J; Perier C
    J Nutr Health Aging; 2003; 7(4):263-6. PubMed ID: 12917752
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders.
    Yamagishi S
    Rejuvenation Res; 2012 Dec; 15(6):564-72. PubMed ID: 22950433
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive analysis of maillard protein modifications in human lenses: effect of age and cataract.
    Smuda M; Henning C; Raghavan CT; Johar K; Vasavada AR; Nagaraj RH; Glomb MA
    Biochemistry; 2015 Apr; 54(15):2500-7. PubMed ID: 25849437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Theoretical studies on models of lysine-arginine cross-links derived from α-oxoaldehydes: a new mechanism for glucosepane formation.
    Nasiri R; Zahedi M; Jamet H; Moosavi-Movahedi AA
    J Mol Model; 2012 Apr; 18(4):1645-59. PubMed ID: 21811778
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two fluorescent wavelengths, 440(ex)/520(em) nm and 370(ex)/440(em) nm, reflect advanced glycation and oxidation end products in human skin without diabetes.
    Beisswenger PJ; Howell S; Mackenzie T; Corstjens H; Muizzuddin N; Matsui MS
    Diabetes Technol Ther; 2012 Mar; 14(3):285-92. PubMed ID: 22023375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks.
    Vasan S; Foiles P; Founds H
    Arch Biochem Biophys; 2003 Nov; 419(1):89-96. PubMed ID: 14568012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Hypothesis: Fructosamine-3-Kinase-Related-Protein (FN3KRP) Catalyzes Deglycation of Maillard Intermediates Directly Downstream from Fructosamines.
    Szwergold B
    Rejuvenation Res; 2021 Aug; 24(4):310-318. PubMed ID: 34314247
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Site-specific synthesis of Amadori-modified peptides on solid phase.
    Frolov A; Singer D; Hoffmann R
    J Pept Sci; 2006 Jun; 12(6):389-95. PubMed ID: 16342332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification.
    Schalkwijk CG; Stehouwer CD; van Hinsbergh VW
    Diabetes Metab Res Rev; 2004; 20(5):369-82. PubMed ID: 15343583
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sugar-mediated crosslinking of alpha-biotinylated-Lys to cysteamine-agarose support: a method to isolate Maillard Lys-Lys-like crosslinks.
    Linetsky M; LeGrand RD; Mossine VV; Ortwerth BJ
    Appl Biochem Biotechnol; 2001 Apr; 94(1):71-96. PubMed ID: 11393357
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Proteins modified in the nonenzymatically glycosylation reaction (AGE-proteins)--new markers for diabetes?].
    Zdrojewicz Z; Januszewski A; Kwiatkowska D
    Postepy Hig Med Dosw; 1994; 48(6):689-700. PubMed ID: 7675730
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protein fructosylation: fructose and the Maillard reaction.
    Dills WL
    Am J Clin Nutr; 1993 Nov; 58(5 Suppl):779S-787S. PubMed ID: 8213610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.